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Abstract
Purpose While chemotherapy has improved survival among younger women with breast cancer, it can induce temporary 
or permanent chemotherapy-related amenorrhoea (CRA), impacting survival benefit, quality of life and, importantly for 
younger patients, fertility.
Methods This single institution retrospective study of 107 premenopausal women with early stage breast cancer who received 
neoadjuvant or adjuvant combined chemotherapy treatment investigates the association of clinicopathological factors (includ-
ing age-related, gynaecological and tumour-related variables) with CRA and resumption of menses using generalised linear 
models for univariable and multivariate analyses.
Results 76% of women developed CRA, of which only 40% resumed menses after treatment. Age at time of treatment 
and at menarche were significantly associated with CRA incidence, with higher rates linked to older age (≥ 40 years) and 
later menarche (at ≥ 13 years), in both univariable (P = 0.043 and P = 0.009, respectively) and multivariate (P = 0.010 and 
P = 0.012, respectively) analyses. Age at time of treatment, age at menarche and use of tamoxifen were significantly asso-
ciated with resumption of menses (with greater resumption rates linked to younger age (< 40 years old), later menarche 
(≥ 13 years old) or no tamoxifen use status), in both univariable (P < 0.0001, P = 0.002 and P = 0.039, respectively) and 
multivariate (P = 0.001, P = 0.011 and P = 0.008, respectively) analyses. Menses resumption rates were also significantly 
higher (P = 0.015) in women with later cessation of menses (after 3–6 chemotherapy cycles rather than sooner).
Conclusions Age at menarche and, specially, at time of treatment are important risk factors for CRA. These variables could 
aid decision-making for treatment selection and fertility preservation among premenopausal women with early breast cancer.
Keywords Chemotherapy · Amenorrhoea · Chemotherapy-related amenorrhoea · Fertility · Premenopausal women · Early 
breast cancer
Introduction
Breast cancer is the most common invasive cancer diag-
nosed in women of reproductive age and, indeed, around 
25–30% of all breast cancers are diagnosed in premeno-
pausal women [1–3]. Consensus guidelines recommend 
the use of neoadjuvant or adjuvant chemotherapy for the 
treatment of this group and studies have demonstrated 
both a disease-free and overall survival benefit from 
its use [4, 5]. Although the majority of premenopausal 
women with early stage breast cancer have an excellent 
prognosis, the use of neoadjuvant or adjuvant chemo-
therapy can also induce a number of off-target effects, 
including temporary or permanent chemotherapy-related 
amenorrhoea (CRA) [6]. This is thought to result from 
interference with follicular maturation and potential 
depletion of the primordial follicles [7–9]. Indeed, the 
risk of CRA associated with alkylating agents or anthra-
cyclines has been shown to range from 53 to 89% [10, 11]. 
One study of 78 premenopausal women reported a CRA 
rate of 44.87% with the FEC regimen (combination ther-
apy with 5-flurouracil, epirubicin and cyclophosphamide) 
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and 23.08% in 66 patients treated with epirubicin plus 
docetaxel [12]. While some studies have reported a 
favourable effect from CRA on disease outcome for 
some premenopausal women, the possible induction of 
early menopause due to cancer treatment can also have 
considerable ramifications including fertility issues (of 
particular importance as more women over the age of 35 
consider pregnancy than ever before), sexual dysfunction 
and, as a result, reduced overall quality of life [6, 13]. 
While the rate of CRA has been shown to vary with age 
and chemotherapy dose and regimens administered [3], 
few studies to date have investigated the importance of 
other clinicopathological factors. In this single institu-
tion retrospective study of 107 premenopausal women 
with early stage breast cancer, we investigated the asso-
ciation of clinicopathological factors with CRA and the 
resumption of menses after completion of neoadjuvant 
or adjuvant combined alkylating agent and anthracycline 
chemotherapy plus or minus a taxane.
Material and methods
Patients
This is a retrospective study of a cohort of patients (n = 112) 
who were treated with chemotherapy (adjuvant or neoad-
juvant) for early stage breast cancer (any grade, any histo-
logical type, any ER status, HER2 negative only, with or 
without nodal disease) at King’s College hospital, London, 
between the years of 2005 and 2010 following appropriate 
multidisciplinary team discussion. Of the 112 patients, 5 had 
non-menses prior to the commencement of chemotherapy 
treatment and were excluded from the analysis, giving a final 
study cohort of 107 women. All patients had yearly follow-
ups for 5 years upon completion of their treatment. Informa-
tion that was not available at the time through their records, 
on menarche, menopause, CRA, parity, smoking status and 
gynaecological history were collected by questionnaire at 
their yearly follow-up (1–5 year). All patients provided writ-
ten consent for their clinical data to be reviewed.
Patient characteristics
At the time of treatment initiation 85% of the patients had 
regular and 15% had irregular menses. The median age for 
the cohort was 43 years (range = 35–50 years old) and the 
median age at menarche was 13 (range = 8–19 years old). 
The median parity was 2 (range = 0–7) with 54% having 
had two or more children. At 12 months from chemotherapy 
completion 16 patients (15%) were premenopausal, 23 (21%) 
were perimenopausal and 68 (64%) were postmenopausal. 
Patient characteristics for the cohort of 107 included in the 
study are summarised in Table 1. 24 patients (22%) reported 
a previous gynaecological medical history—full details are 
given in Table 2.
Table 1  Patient characteristics and clinical data for the study cohort 
(n = 107)
Group Number of patients
Age at treatment < 40 24 (22%)
≥ 40 83 (78%)
Age at menarche < 13 324 (22%)
≥ 13 83 (78%)
Parity 0 21 (20%)
≥ 1 86 (80%)
Pre-treatment menses regular-
ity
Regular 91 (85%)
Irregular 16 (15%)
ER Status Positive 76 (71%)
Negative 31 (19%)
Gynaecological history Yes 25 (23%)
No 82 (77%)
Smoking status Smoker 17 (16%)
Non-smoker 69 (65%)
Ex-smoker 20 (19%)
Menopausal symptoms at time 
of data collection
Premenopausal 16 (15%)
Perimenopausal 23 (21%)
Postmenopausal 68 (64%)
Table 2  Summary of reported previous medical histories of gynaeco-
logical conditions in the study cohort (n = 107)
Gynaecological history condition Num-
ber of 
patients
No gynaecological history 83
C-section 1
Colposcopy 2001 1
Endometriosis; CIN 3 & colposcopy 1
Fibroids 3
Fibroids - hysterectomy 1
Fibroids and menorrhagia 2
Fibroids; DUB 1
Fibroids; menorrhagia 1
HIV+ 1
Ligation of Fallopian tubes 1
Menorrhagia 1
Menorrhagia; ovarian cystectomy; adenoma 1
POS 5
Sterilised 1
Uterine polypectomy 1
Vaginal prolapse 1
Polypectomy 1
Breast Cancer Research and Treatment 
1 3
Treatments
All patients received neoadjuvant or adjuvant chemotherapy. 
66 (62%) with node-negative disease received the FEC75 
regimen (5-fluorouracil 500 mg/m2, epirubicin 75 mg/m2, 
cyclophosphamide 500 mg/m2), in the adjuvant setting and 
41 (38%) with node-positive disease received FEC-T (com-
bination therapy including 3 cycles of 5-fluorouracil 500 mg/
m2, epirubicin 100 mg/m2, cyclophosphamide 500 mg/m2 
followed by 3 cycles of docetaxel 100 mg/m2) either neo-
adjuvantly or in the adjuvant setting). Chemotherapy was 
given on day 1 every 3 weeks for 6 cycles. All patients 
completed the treatment schedule. In addition, 72 patients 
(67%) presented with estrogen receptor alpha (ER)-positive 
breast cancer at diagnosis and 67 (93%) also received adju-
vant tamoxifen after completion of chemotherapy. The five 
patients who did not receive tamoxifen had contraindications 
due to previous DVT. All patients included in the study were 
HER2-negative and therefore none of the above patients 
received trastuzumab.
Statistics
The explanatory variables for analysis of CRA were age at 
time of treatment, age at menarche, parity, pre-treatment reg-
ularity of menses, previous gynaecological medical history, 
ER status of breast cancer (all ER-positive patients received 
adjuvant tamoxifen), chemotherapy regimen/lymph node sta-
tus and smoking status. Median, percentiles and range were 
analysed for each continuous variable. Explanatory variables 
were analysed using generalised linear models for univari-
able and multivariate analyses. All statistical analyses were 
performed in IBM SPSS statistics 25.
Results
Incidence of CRA 
All of the women in the study (n = 107) had menses prior to 
the commencement of chemotherapy. 91 (85%) had regular 
menses, while the remaining 16 (15%) reported irregular 
menses (length of cycle > 35 days or abnormal variation in 
duration of cycle). Irregular menses prior to treatment was 
found to be associated with age (P = 0.011), with a higher 
rate recorded in older women. Interestingly, women with 
irregular menses prior to treatment were also significantly 
more likely to have ER-positive breast cancer (P = 0.038), 
although only age was retained as significant in multivari-
ate analysis. No other factors were associated with irregular 
menses prior to treatment.
In total, 81 women (76%) developed amenorrhoea dur-
ing chemotherapy treatment. Of these, 66 (81%) had regular 
menses prior to treatment and 15 (19%) reported irregu-
lar menses. All but one (15/16, 94%) of the women with 
irregular menses prior to the start of treatment developed 
amenorrhoea on chemotherapy (Fig. 1). The rates of per-
manent amenorrhoea were 40.1% in women who reported 
regular menses prior to treatment and 75% in women who 
had irregular menses.
Of the 81 women who reported amenorrhoea on chemo-
therapy, 55 also reported when, during treatment, menses 
stopped. For the majority of women, menses stopped early 
in treatment. For 21 women (38% of those who answered 
this question), menses stopped after a single cycle of chemo-
therapy, for a further 19 women (35%) menses stopped after 
2 cycles and for 12 women (22%) after 3 cycles. Only 3 
women (5%) reported that menses stopped during chemo-
therapy cycles 4 to 6. Only age at time of treatment was 
found to be significantly associated (P = 0.002) with time 
during treatment when menses stopped. No women under 
40 years old reported menses stopping after a single cycle of 
chemotherapy, but the rate was 44% in women over 40 years 
old.
Of the 26 women (24%) in the study population who con-
tinued menses during chemotherapy, 17 (65%) had regular 
menses prior to treatment and developed irregular menses 
during treatment. After completion of chemotherapy 10 
of these 17 women resumed regular menses in a period of 
4–12 months after treatment completion, while 5 remained 
irregular and 3 developed post-treatment amenorrhoea. In 
total, only 7 women in the study cohort (7%), had regular 
menses prior to chemotherapy and reported no change in 
menses during or after treatment (Fig. 1).
Variables associated with CRA 
Table 3 shows the incidence and rate of CRA in respect 
of the explanatory variables studied. Age at time of treat-
ment as a continuous variable was found to be significantly 
associated with incidence of CRA (P = 0.043) with sig-
nificantly higher rates (82%) in women 40 years or older 
compared with women under 40 (54%) (P = 0.008). Age 
at menarche as a continuous variable was also found to be 
significantly associated with incidence of CRA (P = 0.002) 
with significantly higher rates (82%) in women who began 
menarche later (≥ 13 years old) compared with women who 
began menarche at a younger age (< 13 years old) (54%) 
(P = 0.009). No other explanatory variables were associ-
ated with incidence of CRA. There was no direct statistical 
association (P = 0.128) or correlation (R = -0.009) between 
age at time of treatment and age at menarche and in multi-
variate generalised linear model analysis both age at treat-
ment (P = 0.010, OR 0.262, 95% CI 0.094–0.727) and age 
at menarche (P = 0.012, OR 0.297, 95% CI 0.114–0.770) 
were significant and contributed to the final model. The rate 
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Fig. 1  Schematic representing the proportional incidence of CRA and menses resumption following chemotherapy in the study cohort, sub-
grouped by regularity of pre-treatment menses
Table 3  Association of patient characteristics and clinical data with incidence and rate of CRA and resumption of menses in those with CRA in 
the study population
Bold values indicate statistical significance of P-value < 0.05
Group CRA incidence Incidence of menses resumption following CRA 
CRA 
cases per 
group
Rate of 
CRA per 
group
P-value Resumption of men-
ses after CRA per 
group
Rate of resumption of 
menses after CRA per 
group
P-value
Age at treatment < 40 13/24 54% 0.008 12/13 92% 0.002
≥ 40 68/83 82% 20/68 29%
Age at menarche < 13 13/24 54% 0.009 3/13 23% 0.027
≥ 13 68/83 82% 29/68 43%
Pre-treatment menses regularity Regular 66/91 73% 0.068 29/66 43% 0.087
Irregular 15/16 94% 3/15 20%
Parity 0 17/21 81% 0.531 6/17 35% 0.689
≥1 64/86 74% 26/64 41%
ER status Positive 60/76 79% 0.220 18/60 30% 0.004
Negative 21/31 68% 14/21 67%
Gynaecological history Yes 20/25 80% 0.322 9/20 45% 0.562
No 61/82 74% 23/61 38%
Smoking status Smoker 13/17 76% 0.059 6/13 46% 0.593
Non-smoker 49/70 71% 18/49 37%
Ex-smoker 19/20 95% 8/19 42%
Chemotherapy regimen/lymph 
node status
FEC-T 50/66 77% 0.986 22/50 44% 0.293
FEC75 31/41 76% 10/31 32%
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of CRA was 89% in women 40 years or older who began 
menarche at 13 years or older. Conversely, the rate in women 
under 40 who entered menarche before age 13 was 37% 
(Fig. 2a). 
Resumption of menses following CRA 
The overall rate of permanent CRA in the study popula-
tion was 49.5%. Menses resumed after treatment in only 
32 patients of 81 who developed CRA (40%). Of these, 
29 women (91%) with regular menses prior to treatment 
resumed menses after treatment: 16 with regular menses and 
13 with irregular menses. One patient who reported irregu-
lar menses before treatment resumed irregular menses after 
treatment. Interestingly, 2 patients with irregular menses 
prior to treatment resumed regular menses after completion 
of chemotherapy.
Variables associated with resumption of menses 
following CRA 
Table 3 shows the rates of menses resumption in those 
patients who developed CRA in respect of the explanatory 
variables studied. Age at time of treatment as a continuous 
variable was highly significantly associated with resumption 
of menses following CRA (P < 0.0001). Women less than 
40 years of age were more likely to resume menses after 
completion of chemotherapy (P = 0.002). Age at menarche 
as a continuous variable was also found to be significantly 
associated with resumption of menses following CRA 
(P = 0.027) with significantly higher rates of resumption 
(48%) in women who began menarche later (≥ 13 years old) 
compared with women who began menarche at a younger 
age (< 13 years old) (19%) (P = 0.013). Tamoxifen treat-
ment was also found to be a significant predictor of menses 
resumption in univariable analysis (P = 0.039). In compari-
son to tamoxifen-naive cancers, women with ER-positive 
cancers treated with tamoxifen were less likely to resume 
menses after treatment. Within the subgroup (n = 55) for 
which time of CRA time of onset data were available, anal-
ysis showed that resumption of menses was significantly 
associated (P = 0.015) with later cessation of menses during 
chemotherapy treatment. In this cohort, a greater proportion 
of patients (45%) reported development of CRA after cycles 
3–6 of chemotherapy in the subgroup of 20 patients (36%) 
who resumed menses after treatment compared with only 
17% in the subgroup of 35 patients (64%) who developed 
permanent CRA. Conversely, fewer patients report CRA 
Age <40 Age ≥40
Age at 
menarche <13 37% 70%
Age at 
menarche ≥13 67% 89%
Development of Overall CRAA
B
C
Tamoxifen 
Treatment
No Tamoxifen
Treatment
Ag
e 
at
 M
en
ar
ch
e
Development of Permanent CRA
Permanent CRA
Resumed menses
Fig. 2  a Rates of overall CRA in respect of associated explanatory 
variables: age at treatment and age at menarche. The highest rates 
(red) occurred in women aged 40 or older who began menarche 
aged 13 or older. The lowest rates (green) were found in women 
aged less than 40 who began menarche before the age of 13. b Pie 
charts showing after which chemotherapy cycle CRA developed in 
the patients for whom this data was reported (n = 55). Comparisons 
are made between the subgroup of patients who resumed menses 
after treatment (green) and those who developed permanent CRA 
(dark blue). Smaller pie charts show the proportions of patients in 
each subgroup that reported CRA after 1 chemotherapy cycle (blue), 
2 cycles (orange) and 3 or more cycles (grey). c Scatterplot showing 
the most significant explanatory variables from the regression analy-
sis. Horizontal panels mean age at diagnosis for each subgroup, verti-
cal panels mean age at menarche for each subgroup. Red subgroup of 
patients who developed permanent CRA, blue subgroup of patients 
who resumed menses after CRA 
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after only 1 cycle of chemotherapy in the group who later 
resumed menses compared with the group who remained 
permanently amenorrhoeic (25% vs 46%) (Fig. 2b). In mul-
tivariate analysis, age at time of treatment (P = 0.001, OR 
0.020, 95% CI 0.002–0.022), age at menarche (P = 0.011, 
OR 8.356, 95% CI 1.632–42.788) and tamoxifen treatment 
(P = 0.011, OR 0.184, 95% CI 0.052–0.660) remained signif-
icant and contributed to the final model. Age at time of treat-
ment was found to be the most significant factor and overall 
the rate of permanent CRA in women 40 years and older was 
71% compared to 14% in women under 40, irrespective of 
tamoxifen treatment or age of menarche (Fig. 2c).
Discussion
Adjuvant chemotherapy for premenopausal women
Adjuvant chemotherapy has significantly improved the dis-
ease-free and overall survival of younger women diagnosed 
with breast cancer [5, 14]. However, the use of chemother-
apy is associated with a number of side effects, due to the 
non-specific targeting of normal proliferating cells, and these 
can include gastrointestinal reactions, myelosuppression and 
suppression or ablation of ovarian function [15, 16]. In this 
retrospective study we have specifically evaluated CRA in a 
cohort of women with early stage breast cancer who received 
adjuvant or neoadjuvant chemotherapy prior to the onset of 
menopause.
In the study cohort 15% of patients reported irregular 
menses prior to the commencement of chemotherapy and 
this was strongly associated with age, with older patients 
were more likely to have irregular menses. Indeed, this can 
be attributed to the decreasing number of active ovarian fol-
licles found with increasing age.
Factors associated with CRA 
The rate of CRA in the study group was 76%, which is 
consistent with previous studies investigating incidence 
of CRA in premenopausal women receiving alkylating or 
anthracycline-based chemotherapies [10, 11]. As expected, 
age was strongly associated with both CRA incidence and 
development of CRA early in treatment, with women aged 
over 40 years old more likely to develop CRA early during 
chemotherapy treatment [12]. Consistent with one study of 
431 premenopausal women [17], age at menarche was also 
strongly associated with CRA. Using a cut-off of 13 years 
old, the reported UK median age of menarche [18], our 
results suggest that women who commenced menarche later 
were more likely to develop CRA. Interestingly, these age-
related variables were independent, with no statistical asso-
ciation found between the groups. In multivariate analysis 
both variables were retained and were found to contribute 
significantly to the final model. None of the other variables 
evaluated were found to have a statistical association with 
development of CRA. Specifically, we compared rates of 
CRA between patients who received FEC75 with those who 
received an additional taxane (FEC-T). In accordance with 
a previous study of 165 premenopausal women [19], the 
addition of a taxane to the standard FEC75 chemotherapy 
regimen was not found to increase the rate of CRA.
Factors associated with resumption of menses 
after CRA 
As expected, resumption of menses was significantly asso-
ciated with younger age at time of treatment and older age 
at menarche. In a subset analysis (n = 55), resumption was 
also significantly associated with CRA development later 
in chemotherapy treatment. In the study population women 
with tamoxifen-naive breast cancer, the vast majority of 
which was ER-negative (86%), were also found to be more 
likely to resume menses compared with those with ER-
positive disease who received adjuvant tamoxifen. This is 
consistent with studies that have shown that tamoxifen can 
delay the resumption of menses [20]. Overall, age at time of 
treatment was found to be the most significant explanatory 
variable in univariable and multivariate analysis. None of 
the other variables evaluated were found to have a statistical 
association with resumption of menses.
Implications of CRA 
Some studies have reported that CRA can provide a sur-
vival benefit in some groups of women, particularly younger 
women with ER-positive breast cancer [21–25]. It is thought 
that this survival advantage results from the indirect endo-
crine effect of the chemotherapy on ovarian function in addi-
tion to its cytotoxic effect. In support of this, the Zoladex 
Early Breast cancer Research Association (ZEBRA) trial 
provided evidence for this dual effect. In the trial, premeno-
pausal women were randomised to 2 years of monthly goser-
elin (gonadotropin releasing hormone (GnRH) superagonist) 
to block ovarian function or six cycles of chemotherapy. 
Patients with hormone-sensitive breast cancer were found 
to have equivalent disease-free survival with either treat-
ment, whereas those with hormone-insensitive disease had 
improved survival with chemotherapy [26]. That said, more 
recent evidence suggests that chemotherapy alone is not suf-
ficient for the treatment of younger women with ER-positive 
breast cancer. One trial demonstrated inferior survival in 
women younger than 35 years old treated with chemotherapy 
alone compared with ER-negative disease [27] and another 
retrospective analysis of 5879 premenopausal women 
treated with chemotherapy alone reported a significantly 
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higher recurrence rate in women under 35 years old com-
pared with those over [28]. Young women are less likely to 
develop CRA and it is thought that this inadequate endocrine 
manipulation accounts for the worse prognosis previously 
reported in this group with chemotherapy alone [10, 21, 22, 
24, 26, 29–34]. Consequently, adjuvant tamoxifen, in addi-
tion to chemotherapy, is recommended for the treatment of 
young women with ER-positive disease. A number of stud-
ies have reported that tamoxifen use in addition to chemo-
therapy increases the rate of CRA and delays the resumption 
of menses. However, the International Breast Cancer Study 
Group Trial 13–93, which enrolled 1246 premenopausal 
women, reported no statistically significant difference in 
rates of CRA between patients who received tamoxifen and 
those who did not [3, 21]. Data from the SOFT/TEXT trial 
suggests that ovarian suppression is superior with GnRH 
plus exemestane compared with either GnRH plus tamoxifen 
or tamoxifen alone [35].
Despite the fact that chemotherapy and endocrine ther-
apy have both been shown to improve outcome in younger 
women with ER-positive breast cancer, there is some debate 
as to the prognostic relevance of CRA and subsequent 
resumption of menses after CRA in this group. A meta-anal-
ysis of 5513 premenopausal women demonstrated that CRA 
was a beneficial factor for breast cancer prognosis regard-
less of whether tamoxifen was administered [36]. One study 
of 249 women reported that resumption of menses was not 
associated with poor prognosis [11] while another study of 
872 women reported that resumption of menses was an indi-
cator of poor prognosis [37].
CRA also has important implications for fertility and 
there is a need to address the concerns of younger women 
who want to remain fertile to have children after a diagnosis 
of breast cancer [6, 12]. Most women who remain amenor-
rhoeic 1 year after completion of chemotherapy are unlikely 
to regain ovarian function, resulting in loss of child-bearing 
potential [38]. Steps to maintain fertility in women at risk 
include the use of GnRH agonists, cryopreservation tech-
niques and collection and storage of eggs.
Study limitations
While the overall findings of this study are consistent with 
previous studies, the detail described in this study about 
the likely long-term consequences of timing of cessation 
of menses during chemotherapy treatment and the later 
resumption or failure of resumption are not well described 
in previous studies, and this small retrospective study adds 
useful data to support clinicians treating such patients. That 
said, we acknowledge that amenorrhoea is an imperfect sur-
rogate of ovarian failure, however, this was selected as an 
endpoint as it represents an easily measurable variable that 
is widely used in the clinical setting. Since we have collected 
the above data there has been a growing body of evidence 
supporting the use of anti-Müllerian hormone (AMH) serum 
levels as a biomarker of ovarian reserve in patients being 
treated for cancer. AMH levels taken post-treatment may be 
able to guide advice regarding remaining reproductive lifes-
pan and aid decision-making on suitable adjuvant hormo-
nal treatments such as in hormone receptor-positive breast 
cancer [39]. Moreover Anderson and Cameron [40] showed 
that long-term ovarian function after chemotherapy could be 
predicted by pre-treatment serum AMH concentration. This 
may also be of value in counselling the patient regarding the 
need for fertility preservation procedures before commenc-
ing therapy [40].
We also acknowledge that due to the retrospective nature 
of this study the chemotherapy regimen used (FEC75 × 6), 
with a large cumulative dose of cyclophosphamide, a drug 
previously reported to be linked to amenorrhoea, is less 
favoured today. Dose dense chemotherapy regimens are 
now widely used replacing the previous standard combina-
tion regimens of FEC or FEC-T. Platinum agents are also 
widely used and especially in women keen to preserve fertil-
ity docetaxel-carboplatin combination regimens are favoured 
when possible. There are no data in literature with regards 
to the effects of these regimens on fertility and ovarian 
preservation. We have secured funding and obtained ethical 
approvals to conduct a follow-up study similar in design to 
the current using though dose dense epirubicin/cyclophos-
phamide-docetaxel and platinum-based chemotherapy regi-
mens and the results of this retrospective study will be used 
for comparison purposes. This study will also include pre-
treatment and post-treatment measurements of AMH, FSH, 
LH, oestradiol and patients will be followed up for 5 years 
with blood collections to measure the above parameters on 
a yearly basis. Assessing these parameters in pre- and post-
chemotherapy longitudinal samples might be also useful in 
possibly determining the ovarian reserve in women using 
IUS contraception at the time of diagnosis given that the 
number of these women has gone up the recent years.
Conclusions
Given that CRA and subsequent resumption of menses may 
have important implications for survival benefit, future fer-
tility and quality of life in some groups of patients, it is 
important to understand which factors are most associated 
with these phenomena to tailor treatments and take steps to 
preserve fertility. In this study we have analysed a number 
of clinicopathological variables and their association with 
CRA development and resumption of menses. We have con-
firmed the importance of both age at time of treatment and 
age at menarche for risk of developing either temporary or 
permanent CRA. Our data also suggests that age at time 
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of treatment remains the single most important variable for 
determining the likelihood of developing permanent CRA.
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